Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AstraZeneca
Woman Max 99 years
AstraZeneca GmbH
Update Il y a 4 ans
Addition of vandetanib to standard therapy (pegliposomal doxorubicin) in patients with recurrent ovarian cancer. A multi-centre, non-randomized, open phase I/randomized phase II study
to evaluate the tolerability and safety of once daily oral Vandetanib 100 mg when added to standard therapy (pegliposomal doxorubicin 50 mg/m2 iv every 4 weeks) compared to standard therapy alone (peg...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A 52-Week International, Multi-centre, Randomised, Parallel-group, Double-blind, Active-controlled, Phase III study with a 52-Week Extension Period to Evaluate the Safety and Efficacy of Saxagliptin in Combination with Metformin compared with Sulphonylurea in Combination with Metformin in Adult Patients with Type 2 Diabetes who have Inadequate Glycaemic Control on Metformin Therapy Alone
To compare that after 52-week oral administration of double-blind treatment, the absolute change from baseline in glycosylated haemoglobin A1c (HBA1c) level with saxagliptin plus metformin is non-inf...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A late stage clinical trial to investigate the efficacy and safety of AZD9291 versus Placebo in patients with stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy
To assess the efficacy of AZD9291 compared to placebo as measured by disease free survival (DFS)
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg ‘as needed’ compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg ‘as needed’
To demonstrate that Symbicort Turbuhaler 160/4.5 μg ‘as needed’ is non-inferior to Pulmicort Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg ‘as needed’
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Phase II, double-blind, randomized, cross-over, international, multicentre study to evaluate the analgesic efficacy of 3 weeks oral administration of AZD4282 300 mg b.i.d. compared with placebo in postherpetic neuralgia
To evaluate the analgesic efficacy of 3 weeks oral administration of AZD4282 compared with placebo in postherpetic neuralgia.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A 4-week, phase-II, double-blind, placebo-controlled, randomized, parallel group, multi-centre study to assess the efficacy and tolerability/safety of inhaled AZD3199 once daily compared to 9 μg formoterol bid and placebo in patients with moderate to severe COPD
Primary objective is: • To compare the clinical efficacy of AZD3199 inhaled once daily with 9 μg formoterol twice daily and placebo over a 4-week treatment period in adults with chronic obstructive pu...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
AstraZeneca
Update Il y a 6 ans
Étude ADAURA : étude de phase 3 randomisée comparant l’efficacité et la sécurité de l’osimertinib (AZD9291) avec celles d’un placebo chez des patients ayant un cancer du poumon non à petites cellules de stade IB-IIIA avec mutation de l’EGFR. [Informations issues du site clinicaltrials.gov et traduites par l'INCa]
Le cancer du poumon se développe à partir de cellules situées dans le poumon qui se multiplient de manière anormale pour former une masse ou tumeur. Le cancer du poumon non à petites cellules est le t...
Country
France
organs
Poumon, type non à petites cellules
Specialty
Thérapies Ciblées
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A phase II, double-blind, placebo-controlled, randomised, 6-way cross-over, single-dose study to investigate the local and systemic effects of 3 doses of inhaled AZD3199 (a β2-agonist) compared to formoterol in asthmatic patients
The primary objective of the study is to investigate the pharmacodynamics of AZD3199 inhaled via Turbuhaler compared to placebo and inhaled formoterol. The primary variable for local pulmonary effec...
Country
None
organs
None
Specialty
None
unknown
More information
AstraZeneca Clinical Research Group (UK)
Update Il y a 4 ans
Pan-European Trials in Adjuvant Colon Cancer. PETACC-1: The Value of Tomudex Relative to Standard Leucovorin Modulated Bolus 5-Fluorouracil (5-FU)
Not provided at time of registration
Country
United Kingdom
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Phase II, Randomised, Factorial, Double-blind Study to Investigate the Management of AZD2171-induced Hypertension and Efficacy of AZD2171 at Doses of 30 mg and 45 mg in Patients with Advanced Solid Tumours
In order to investigate the hypothesis that withdrawal of AZD2171 can be avoided by controlled anti-hypertensive therapy, the primary objective of the study is to identify a treatment strategy, consis...
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
9
10
11
12
13
14
15
16
17
18
Next